Canadian Chronic Disease Surveillance System (CCDSS)

Select item(s) from each list below:

Geography

Condition

Measure

Sex
Both sexes
Males Females
Use the same vertical axis scale across all sex categories

Optional:

Year range

Scale
Use the same vertical axis scale across all geographic areas

Chart type
Line Bar

For more information on the interpretation of the data please see the notes below.

Summary Table: Rheumatoid arthritis, age-standardized incidence rate, per 100,000, age 16 years and older, Canada
Sex	Fiscal year	Rate (per 100,000)	95% CI	CV (%)	Counts
Both sexes	2007–2008	90	89–91	0.65	23,780
Both sexes	2008–2009	91	90–92	0.63	24,925
Both sexes	2009–2010	87	85–88	0.64	24,280
Both sexes	2010–2011	84	83–85	0.64	24,160
Both sexes	2011–2012	86	85–88	0.63	25,390
Both sexes	2012–2013	82	81–83	0.64	24,765
Both sexes	2013–2014	78	77–79	0.65	24,050
Both sexes	2014–2015	77	76–78	0.65	24,030
Both sexes	2015–2016	79	78–80	0.63	25,175
Both sexes	2016–2017	76	75–77	0.64	24,675
Both sexes	2017–2018	77	76–78	0.63	25,585
Both sexes	2018–2019	78	77–79	0.62	26,465
Both sexes	2019–2020	80	79–81	0.61	27,495
Both sexes	2020–2021*	83	82–84	0.60	28,890
Both sexes	2021–2022*	78	77–79	0.62	27,300
Both sexes	2022–2023*	76	75–77	0.62	27,070
Males	2007–2008	62	61–63	1.14	7,735
Males	2008–2009	63	61–64	1.12	8,125
Males	2009–2010	59	57–60	1.13	7,825
Males	2010–2011	58	57–59	1.13	7,935
Males	2011–2012	59	58–60	1.10	8,290
Males	2012–2013	56	55–58	1.11	8,110
Males	2013–2014	54	53–55	1.13	7,930
Males	2014–2015	53	52–54	1.12	7,980
Males	2015–2016	55	54–56	1.09	8,485
Males	2016–2017	53	52–54	1.10	8,355
Males	2017–2018	54	52–55	1.08	8,670
Males	2018–2019	55	54–56	1.06	9,040
Males	2019–2020	56	55–57	1.04	9,485
Males	2020–2021*	58	57–59	1.01	9,970
Males	2021–2022*	54	53–55	1.05	9,300
Males	2022–2023*	52	51–53	1.06	9,255
Females	2007–2008	116	114–118	0.79	16,050
Females	2008–2009	118	116–119	0.78	16,795
Females	2009–2010	113	111–115	0.78	16,455
Females	2010–2011	109	107–111	0.79	16,220
Females	2011–2012	113	111–114	0.77	17,105
Females	2012–2013	108	106–109	0.78	16,655
Females	2013–2014	102	101–104	0.79	16,120
Females	2014–2015	100	98–102	0.80	16,050
Females	2015–2016	102	101–104	0.78	16,685
Females	2016–2017	98	97–100	0.79	16,325
Females	2017–2018	101	99–102	0.78	16,915
Females	2018–2019	102	100–103	0.77	17,425
Females	2019–2020	103	102–105	0.76	18,005
Females	2020–2021*	107	106–109	0.74	18,920
Females	2021–2022*	103	101–104	0.76	17,995
Females	2022–2023*	101	99–102	0.77	17,820

Download Detailed Table:
Rheumatoid arthritis, age-standardized incidence rate

Download Summary Table

Notes:

*Many CCDSS measures, such as chronic disease incidence, were influenced by the COVID-19 pandemic. Changes in such measures may be driven by multiple factors, including (but not limited to) differences in healthcare seeking behaviour, the availability and use of healthcare services, as well as true changes in health status. As such, CCDSS measures should be used cautiously when making inferences about population health during the COVID-19 pandemic. Guidance for data users on examining the impacts of the COVID-19 pandemic on CCDSS measures can be accessed below.
Data suppression: Estimates are not reported when the counts are less than 10 or the coefficient of variation is greater than 33.3%.
Due to periodic updates of the historical surveillance data, estimates for a particular disease and year may change over time, and may not be comparable to previous editions.
Estimates are age-standardized to the 2011 Canadian population using unrounded counts and five-year age groups. Age-standardized estimates are useful for comparing data across years or between different geographical areas, but they do not reflect the actual impact of the disease.
Nunavut data are excluded before 2005–2006.
Newfoundland and Labrador data are excluded before 2008–2009.
Yukon data are excluded before 2010–2011.
The modernization of the Quebec billing system for fee-for-service medical services by the Régie de l'assurance maladie du Québec (RAMQ) in 2016 has resulted in a decrease in the entry of diagnostic codes in the fee-for-service medical services file. Data for 2016–2017 and subsequent years should therefore be interpreted with caution, as a slight underestimation is suspected.
The introduction of the Northwest Territories Electronic Medical Record (EMR) in 2016 resulted in more complete and consistent data. Data for 2016–2017 may be slightly underestimated compared to previous years due to the system transition.
New Brunswick data were not available for 2021–2022 and 2022–2023.
Northwest Territories data were not available for 2022–2023.
Northwest Territories physician claim data were incomplete for 2021–2022 and should therefore be interpreted with caution, as a slight underestimation is suspected.

Source: Canadian Chronic Disease Surveillance System 2024
Methods: CCDSS Summary of Methods
Case definitions: CCDSS Case Definitions
COVID-19 Documentation: CCDSS COVID-19 guidance for data users

Acknowledgements

These data were made possible through collaboration between PHAC and the respective provincial and territorial governments of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, Northwest Territories, Yukon, and Nunavut. No endorsement by the provinces and territories is intended or should be inferred. Provincial and territorial data were contributed to the CCDSS as of July 2024.

Language selection

Search

Canadian Chronic Disease Surveillance System (CCDSS)

Select item(s) from each list below:

Optional:

Acknowledgements

Did you find what you were looking for?